Investigation of the potential beneficial effects of cannabidiol in the treatment of tardive dyskinesia

Recruiting

• Conditions: Tardive dyskinesia; Nervous System Diseases; Drug-induced dystonia

• Registration Number: ISRCTN14688109
• Lead Sponsor: Stellenbosch University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-05-07
• Last Update Posted: 8 January 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Adults 18 years and older
2. Currently meets the ICD-10 diagnosis of a psychotic disorder, verified with the Mini International Neuropsychiatric Interview (MINI-PLUS) questionnaire.
3. Currently meets the clinical diagnosis of tardive dyskinesia confirmed with the Abnormal Involuntary Movement Scale (AIMS)
4. Patients should currently be receiving treatment for a psychotic disorder and should be on either the atypical or conventional antipsychotics
5. Patient gives informed consent

Exclusion Criteria

1. ICD-10 diagnosis of an organic mental illness, substance misuse disorder or a seizure disorder
2. Serious or chronic physical illness
3. Known severe drug allergies or hypersensitivity to CBD

Study & Design

• Study Type: Interventional
• Study Design: Not specified